RxCelerate acquires UK-based molecular modeling company

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Kritchanut)
(Image: Getty/Kritchanut)

Related tags: RxCelerate

The outsourced drug discovery and development firm has acquired Prosarix, a UK-based molecular modeling company.

The UK-based contract research organization (CRO) RxCelerate opened a US office in Boston in late 2018​. Earlier in the year, the company also acquired the specialist bioanalytical CRO Total Scientific​.

Now, RxCelerate has announced its acquisition of Prosarix, a molecular modeling company that supports both protein engineering and in silico​ drug design projects.

“Following the acquisition of bioanalytical CRO Total Scientific and sector-focused back-office service provider The Cambridge Partnership during 2018, this new acquisition underlines our commitment to complete the jigsaw, so that our clients can access world-leading drug discovery capability under one roof,”​ said RxCelerate Founder and Chairman Dr. David Grainger in a press release.

Prosarix’s ProtoDiscovery platform for small molecule design and protein engineering has been in use since the company’s inception in 2006.

RxCelerate has not responded to a request for comment.

Related topics: Preclinical Research

Related news

Show more

Follow us

Featured Events

View more

Products

View more

Webinars